U.S. markets close in 3 hours 8 minutes
  • S&P 500

    3,996.65
    -6.22 (-0.16%)
     
  • Dow 30

    32,479.58
    -81.02 (-0.25%)
     
  • Nasdaq

    11,857.09
    -3.02 (-0.03%)
     
  • Russell 2000

    1,764.53
    -13.21 (-0.74%)
     
  • Crude Oil

    70.40
    +0.73 (+1.05%)
     
  • Gold

    1,951.40
    +10.30 (+0.53%)
     
  • Silver

    22.83
    +0.40 (+1.78%)
     
  • EUR/USD

    1.0803
    +0.0030 (+0.28%)
     
  • 10-Yr Bond

    3.5710
    -0.0350 (-0.97%)
     
  • GBP/USD

    1.2239
    +0.0020 (+0.16%)
     
  • USD/JPY

    132.5970
    +0.1370 (+0.10%)
     
  • Bitcoin USD

    28,691.91
    +329.46 (+1.16%)
     
  • CMC Crypto 200

    623.00
    +7.06 (+1.15%)
     
  • FTSE 100

    7,566.84
    +30.62 (+0.41%)
     
  • Nikkei 225

    27,466.61
    +520.94 (+1.93%)
     

Medivation price target raised to $105 from $97 at Jefferies

Jefferies raised its price target on Medivation (MDVN) to $105 after positive results were reported for Johnson & Johnson's (JNJ) Zytiga. Jefferies said that it thinks Medivation's enzalutamide could match or beat the overall survival results reported for Zytiga and the firm keeps a Buy rating on Medivation shares.